New non-invasive treatment for incontinence 'offering hope'

A new treatment is offering hope to millions of people suffering with bladder issues, in time for World Continence Week (16–22 June). The UK-first electromagnetic chair uses High-Intensity Focused Electromagnetic (HIFEM) technology to stimulate the pelvic floor muscles.
In just one 28-minute session, it delivers the equivalent of 11,000 Kegel exercises, and users stay fully clothed while they sit in the chair. Bladder problems affect more than 14 million people in the UK, that's around 1 in 4 adults.
'Bladder issues can destroy confidence, relationships, and quality of life,' says Nurse Practitioner Joolia Gilvey from The Clinic Norwich. Supramax changes everything. It's discreet, non-invasive, and actually works. For many, it's the first time they've felt hope in years.'
Developed by Pure Tone Aesthetics, Supramax is the first medically certified chair of its kind available in the UK. The chair is proving particularly helpful for women, who make up the majority of bladder problem sufferers. NHS figures show that one in three women and one in 10 men experience urinary incontinence at some point in their lives.
Clinics report that many patients see results in as little as six sessions, each lasting under half an hour. Treatment courses are now available in clinics nationwide.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

11 minutes ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

South Wales Guardian

26 minutes ago

• South Wales Guardian

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Daily Mail​

32 minutes ago

• Daily Mail​

Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons

A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.